Literature DB >> 11257040

Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

K E Aldridge1, D Ashcraft, K Cambre, C L Pierson, S G Jenkins, J E Rosenblatt.   

Abstract

In vitro surveys of antimicrobial resistance among clinically important anaerobes are an important source of information that can be used for clinical decisions in the choice of empiric antimicrobial therapy. This study surveyed the susceptibilities of 556 clinical anaerobic isolates from four large medical centers using a broth microdilution method. Piperacillin-tazobactam was the only antimicrobial agent to which all the isolates were susceptible. Similarly, imipenem, meropenem, and metronidazole were highly active (resistance, <0.5%), whereas the lowest susceptibility rates were noted for penicillin G, ciprofloxacin, and clindamycin. For most antibiotics, blood isolates were less susceptible than isolates from intra-abdominal, obstetric-gynecologic, and other sources. All isolates of the Bacteroides fragilis group were susceptible to piperacillin-tazobactam and metronidazole, while resistance to imipenem and meropenem was low (<2%). For these same isolates, resistance rates (intermediate and resistant MICs) to ampicillin-sulbactam, cefoxitin, trovafloxacin, and clindamycin were 11, 8, 7, and 29%, respectively. Among the individual species of the B. fragilis group, the highest resistance rates were noted among the following organism-drug combinations: for clindamycin, Bacteroides distasonis and Bacteroides ovatus; for cefoxitin, Bacteroides thetaiotaomicron, B. distasonis, and Bacteroides uniformis; for ampicillin-sulbactam, B. distasonis, B. ovatus, and B. uniformis; and for trovafloxacin, Bacteroides vulgatus. For the carbapenens, imipenem resistance was noted among B. fragilis and meropenem resistance was seen among B. fragilis, B. vulgatus, and B. uniformis. With few exceptions all antimicrobial agents were highly active against isolates of Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus. These data further establish and confirm that clinically important anaerobes can vary widely in their antimicrobial susceptibilities. Fortunately most antimicrobial agents were active against the test isolates. However, concern is warranted for what appears to be a significant increases in resistance to ampicillin-sulbactam and clindamycin.

Entities:  

Mesh:

Year:  2001        PMID: 11257040      PMCID: PMC90449          DOI: 10.1128/AAC.45.4.1238-1243.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  beta-lactamase production and antimicrobial susceptibility of oral heterogeneous Fusobacterium nucleatum populations in young children.

Authors:  E Könönen; A Kanervo; K Salminen; H Jousimies-Somer
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy.

Authors:  P Montravers; R Gauzit; C Muller; J P Marmuse; A Fichelle; J M Desmonts
Journal:  Clin Infect Dis       Date:  1996-09       Impact factor: 9.079

3.  Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996.

Authors:  D R Snydman; N V Jacobus; L A McDermott; S Supran; G J Cuchural; S Finegold; L Harrell; D W Hecht; P Iannini; S Jenkins; C Pierson; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1999-10       Impact factor: 5.191

4.  Comparative activity of eighteen antimicrobial agents against anaerobic bacteria isolated in South Africa.

Authors:  M M Lubbe; P L Botha; L J Chalkley
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1999-01       Impact factor: 3.267

5.  Transferable plasmid-linked chloramphenicol acetyltransferase conferring high-level resistance in Bacteroides uniformis.

Authors:  J V Martínez-Suárez; F Baquero; M Reig; J C Pérez-Díaz
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

6.  Attributable mortality of bacteremia associated with the Bacteroides fragilis group.

Authors:  M C Redondo; M D Arbo; J Grindlinger; D R Snydman
Journal:  Clin Infect Dis       Date:  1995-06       Impact factor: 9.079

Review 7.  The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.

Authors:  K E Aldridge
Journal:  Am J Surg       Date:  1995-05       Impact factor: 2.565

8.  A five-year multicenter study of the susceptibility of the Bacteroides fragilis group isolates to cephalosporins, cephamins, penicillins, clindamycin, and metronidazole in the United States.

Authors:  K E Aldridge; M Gelfand; L B Reller; L W Ayers; C L Pierson; F Schoenknecht; R C Tilton; J Wilkins; A Henderberg; D D Schiro
Journal:  Diagn Microbiol Infect Dis       Date:  1994-04       Impact factor: 2.803

9.  Plasmid-mediated, transferable resistance to clindamycin and erythromycin in Bacteroides fragilis.

Authors:  F P Tally; D R Snydman; S L Gorbach; M H Malamy
Journal:  J Infect Dis       Date:  1979-01       Impact factor: 5.226

10.  Transfer of beta-lactamase-associated cefoxitin resistance in Bacteroides fragilis.

Authors:  G J Cuchural; F P Tally; J R Storey; M H Malamy
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

View more
  44 in total

1.  Lemierre's syndrome in the liver.

Authors:  D Kröll; P Sendi
Journal:  Infection       Date:  2012-04-20       Impact factor: 3.553

2.  Antimicrobial susceptibility patterns for recent clinical isolates of anaerobic bacteria in South Korea.

Authors:  Yangsoon Lee; Yongjung Park; Myung Sook Kim; Dongeun Yong; Seok Hoon Jeong; Kyungwon Lee; Yunsop Chong
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 3.  Antianaerobic antimicrobials: spectrum and susceptibility testing.

Authors:  Itzhak Brook; Hannah M Wexler; Ellie J C Goldstein
Journal:  Clin Microbiol Rev       Date:  2013-07       Impact factor: 26.132

4.  Pharmacodynamics of trovafloxacin and levofloxacin against Bacteroides fragilis in an in vitro pharmacodynamic model.

Authors:  M L Peterson; L B Hovde; D H Wright; G H Brown; A D Hoang; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

5.  Resistance trends of the Bacteroides fragilis group over a 10-year period, 1997 to 2006, in Madrid, Spain.

Authors:  Carmen Betriu; Esther Culebras; María Gómez; Fátima López; Iciar Rodríguez-Avial; Juan J Picazo
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

6.  In vitro susceptibility to selected antibiotics in bacteria of the Bacteroides fragilis group.

Authors:  D Chmelar
Journal:  Folia Microbiol (Praha)       Date:  2009-10-14       Impact factor: 2.099

7.  In vitro activity of ten antibiotics, including tigecycline, against Bacteroides species in Austria.

Authors:  A J Grisold; I Wendelin; E Presterl; R B Raggam; L Masoud; A Badura; E Marth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-07       Impact factor: 3.267

8.  Identification of clinically important anaerobic bacteria by an oligonucleotide array.

Authors:  Yu Tzu Lin; Mario Vaneechoutte; Ay Huey Huang; Lee Jene Teng; Hung-Mo Chen; Shu-Li Su; Tsung Chain Chang
Journal:  J Clin Microbiol       Date:  2010-02-03       Impact factor: 5.948

9.  In vitro activities of newer quinolones against bacteroides group organisms.

Authors:  D R Snydman; N V Jacobus; L A McDermott; R Ruthazer; E Goldstein; S Finegold; L Harrell; D W Hecht; S Jenkins; C Pierson; R Venezia; J Rihs; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

Review 10.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.